A

Agilent TechnologiesNYSE · Life Sciences Tools & Services · Health Care

Previous close

153.69

Change

+3.42 / +2.28%

FinDog View

Neutral

52-Week Range

108.35 – 163.75

P/E (TTM)

29.4

Forward P/E

21.5

Based on consensus earnings for the next 12 months

Market Cap

$43.3B

+3.53%

S&P 500 −2.41% over same period

Volume / Avg Volume

2.5M / 2.0M

1.27× average

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 29.91M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q3 Quarter ended 2026-07	2026-08-26	$1.9B	1.62 / —	+1.68%	Read analysis →
FY2026 Q2 Quarter ended 2026-04	2026-05-27	$1.8B	1.49 / —	+16.87%	Pending
FY2026 Q1 Quarter ended 2026-01	2026-02-25	—	— / —	−3.01%	Pending
FY2025 Q4 Quarter ended 2025-10	2025-11-24	—	— / —	+2.34%	Pending
FY2025 Q3 Quarter ended 2025-07	2025-08-27	—	— / —	+5.28%	Pending
FY2025 Q2 Quarter ended 2025-04	2025-05-28	—	— / —	+2.16%	Pending

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 43 of its 5-year rangeMid-range

5-year range 24.9 – 34.9 · Median 29.9

Last 4 quarters: $380M in buybacks + $286M in dividends, 1.54% of market cap combined

P/E (TTM)

29.4

P/B

5.7

P/S

5.7

Dividend Yield

0.75%

Earnings Reaction

Over the last 6 reports, the stock moved ±5.2% on average on the first trading day after, rising 5 times

Most recent +1.68%

Volatility & Correlation

1-year beta 0.85 · Correlation with S&P 500 0.33Tracks the market

Annualized volatility 33% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 1 · $0.10MNet selling $0.10M

09-04Dolsten MikaelDirectorSell$0.10M634 shares · Avg price 151.38

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q3	1.88	+8.1%	55.5%	0.44	0.36	0.44	1.28
FY2026 Q2	1.84	+10.0%	54.0%	0.40	0.34	0.20	1.20
FY2026 Q1	1.80	+7.0%	52.6%	0.35	0.31	0.18	1.07
FY2025 Q4	1.86	+9.4%	53.2%	0.44	0.43	0.45	1.53
FY2025 Q3	1.74	+10.1%	51.1%	0.36	0.34	0.26	1.18
FY2025 Q2	1.67	+6.0%	51.9%	0.30	0.22	0.11	0.75
FY2025 Q1	1.68	+1.4%	53.5%	0.38	0.32	0.33	1.11
FY2024 Q4	1.70	+0.8%	53.9%	0.41	0.35	0.39	1.23
FY2024 Q3	1.58	−5.6%	54.2%	0.33	0.28	0.36	0.97
FY2024 Q2	1.57	−8.4%	54.4%	0.36	0.31	0.23	1.05
FY2024 Q1	1.66	−5.6%	54.8%	0.38	0.35	0.40	1.18
FY2023 Q4	1.69	−8.7%	54.2%	0.41	0.48	0.43	1.60

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
A	Agilent Technologies	$43.3B	29.4	+8.1%	55.5%	+3.53%	Neutral
LLY	Lilly (Eli)	$1.07T	39.9	+47.7%	85.8%	−3.83%	Bullish	Compare
JNJ	Johnson & Johnson	$644B	30.6	+6.6%	68.2%	+1.87%	Bullish	Compare
ABBV	AbbVie	$464B	73.7	+10.2%	74.7%	+4.87%	Neutral	Compare
MRK	Merck & Co.	$358B	112.2	+5.1%	73.5%	+6.57%	Neutral	Compare
UNH	UnitedHealth Group	$337B	23.9	+0.4%	88.1%	−5.15%	Neutral	Compare
TMO	Thermo Fisher Scientific	$240B	34.4	+10.5%	—	+10.75%	Bullish	Compare
AMGN	Amgen	$203B	23.3	+9.5%	72.0%	−10.26%	Neutral	Compare
GILD	Gilead Sciences	$183B	—	+10.2%	79.8%	+6.31%	Neutral	Compare

The View in One Line

Earnings read is Neutral; revenue margin is somewhat positive but includes one-time gains; guidance slightly below expectations; hold Neutral for now.

Updated 2026-09-16

Notable Institutional Holders

Citadel Advisors · Ken Griffin$146MReduced −39%
Renaissance Technologies$34.2M
Bridgewater Associates · Ray Dalio$3.0MReduced −69%

As of 2026-06-30

Key Events

09-08Management Change
Agilent Chairman Retires; Former Stryker CFO Appointed Director
On September 4, 2026, chairman Boon Hwee Koh retired, and Glenn Boehnlein was appointed as a director, joining the audit and finance committee and the compensation committee.Source ↗
06-25Capital Actions
Agilent Issues $600 Million Senior Notes Due 2032
On June 25, 2026, Agilent completed a private placement of $600 million 4.900% senior notes, with the notes maturing on January 15, 2032.Source ↗
05-27Management Change
Agilent Appoints Tim Downs as Chief Accounting Officer
On May 20, 2026, Agilent appointed Tim Downs as Vice President and Chief Accounting Officer, succeeding the retiring Rodney Gonsalves, who will remain as Vice President of Finance until January 2027.Source ↗
05-04Management Change
Agilent Appoints New Chief Legal Officer, Former CLO Steps Down
On May 4, 2026, Michael Buckner became Agilent's Chief Legal Officer, and Bret DiMarco stepped down the same day as Senior Vice President, Chief Legal Officer, and Secretary, transitioning to special advisor until December 1.Source ↗
04-06Management Change
Agilent Chief Legal Officer to Depart, Stay as Special Advisor Through Year-End
Bret DiMarco will resign as Chief Legal Officer and other roles upon the appointment of a new Chief Legal Officer or by September 30, 2026, and will remain as a special advisor until December 1 at an annual salary of $350,000.Source ↗
04-03Management Change
Chief Legal Officer to Depart, Stay as Special Advisor Through Year-End
Agilent Chief Legal Officer Bret DiMarco will step down by September 30, 2026 or upon the appointment of a new CLO, then remain as a special advisor until December 1 at an annual salary of $350,000.Source ↗

Key Financial Trends

Quarterly Revenue ($B)1.9

Gross Margin55.5%

Free Cash Flow ($B)0.4